News
Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...
Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...
Hims & Hers Health, Inc.'s core growth and product diversification signal long-term potential, despite short-term dips. Click ...
For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...
Ali Eastburn missed her son’s rehearsal dinner — and nearly missed the wedding — when her appendix burst while traveling, ...
Investors must now underwrite opportunities with a “financing risk first” mindset, says Siddhi Capital cofounder Steven Finn.
12h
Medindia on MSNReal-World Side Effects of GLP-1 Drugs Exposed Through Facebook PostsFacebook posts reveal more GI side effects from semaglutide drugs like Ozempic than Mounjaro, offering new insights into ...
Explore how GLP-1a drugs transform the food industry from a threat to an opportunity. Our 36-page strategy briefing outlines the potential for growth by meeting the rising demand for protein, fiber, ...
Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as ...
7h
Zacks.com on MSNWill GLP-1 Demand Drive MCK's Top Line This Earnings Season?MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.
Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...
3h
FOX61 on MSNSettlement reached in lawsuit alleging sales of 'bootleg' GLP-1s without prescriptionsTriggered Brand has agreed to pay $18,500 out of a $300,000 judgment after Attorney General William Tong sued the company in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results